Steven Gagnon - BioForce Nanosciences CoChief Officer

All Insiders . USA . 
Stock . BioForce Nanosciences Holdings . Stakeholders . Insider . Steven Gagnon
BFNH Stock  USD 1.09  0.00  0.00%   

Insider

Steven Gagnon is CoChief Officer of BioForce Nanosciences Holdings
Age 61
Phone757 306 6090
Webhttps://www.bioforceeclipse.com

BioForce Nanosciences Management Efficiency

The company has return on total asset (ROA) of (21.8443) % which means that it has lost $21.8443 on every $100 spent on assets. This is way below average. BioForce Nanosciences' management efficiency ratios could be used to measure how well BioForce Nanosciences manages its routine affairs as well as how well it operates its assets and liabilities.
BioForce Nanosciences Holdings currently holds 156.87 K in liabilities with Debt to Equity (D/E) ratio of 4.61, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioForce Nanosciences has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioForce Nanosciences until it has trouble settling it off, either with new capital or with free cash flow. So, BioForce Nanosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioForce Nanosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioForce to invest in growth at high rates of return. When we think about BioForce Nanosciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Richard MartinPremier Foods Plc
N/A
Mark SherwinThe A2 Milk
N/A
BCom BCommBioharvest Sciences
70
Duncan LeggettPremier Foods Plc
N/A
Amber FinneyArtisan Consumer Goods
44
Martin HuberAryzta AG PK
53
Amanda HartThe A2 Milk
N/A
Jane XuThe A2 Milk
N/A
Brady MillerbergAryzta AG PK
N/A
Marcus OpitzAryzta AG PK
62
Paul ThompsonPremier Foods Plc
N/A
Roger CoppinAvi Ltd ADR
62
Anya HamillLaird Superfood
49
Keith CooperAryzta AG PK
N/A
Jamie EichmanLaird Superfood
46
Brian CornblattBioharvest Sciences
N/A
Armin BieriAryzta AG PK
59
Catherine MakinAvi Ltd ADR
59
David HoodAvi Ltd ADR
66
William DruryArtisan Consumer Goods
61
Urs JordiAryzta AG PK
58
BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, and mass merchandisers under the BioForce Eclipse brand, as well as through online and telemarketing. BIOFORCE NANOSCIENCES operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 2 people. BioForce Nanosciences Holdings [BFNH] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Asset-21.84

BioForce Nanosciences Leadership Team

Elected by the shareholders, the BioForce Nanosciences' board of directors comprises two types of representatives: BioForce Nanosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioForce. The board's role is to monitor BioForce Nanosciences' management team and ensure that shareholders' interests are well served. BioForce Nanosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioForce Nanosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Steven Gagnon, CoChief Officer
Richard Kaiser, Corp CFO
Aleksandr Shapiro, President
John LaViolette, CoChief Officer

BioForce Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BioForce Nanosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-21.84
Current Valuation50.2 M
Shares Outstanding29.27 M
Shares Owned By Insiders82.29 %
Price To Earning(1.52) X
Price To Book866.24 X
Price To Sales3,841 X
Gross Profit4.36 K
EBITDA(501.95 K)
Net Income(501.95 K)

Currently Active Assets on Macroaxis

VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C
MSFTMicrosoft
GMGeneral Motors

Other Information on Investing in BioForce Pink Sheet

BioForce Nanosciences financial ratios help investors to determine whether BioForce Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioForce with respect to the benefits of owning BioForce Nanosciences security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY